Valuation: Ernexa Therapeutics Inc.

Market Cap 3.16M 2.83M 2.62M 2.37M 4.44M 301M 4.51M 31.49M 12.46M 157M 11.87M 11.62M 498M P/E 2026 *
-0.11x
P/E 2027 * -1.04x
Enterprise Value 3.16M 2.83M 2.62M 2.37M 4.44M 301M 4.51M 31.49M 12.46M 157M 11.87M 11.62M 498M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
70.47%
Yield 2026 *
-
Yield 2027 * -
10-22 Ernexa Therapeutics Highlights ERNA-101?s Path Toward The Clinic And Differentiated Cell Therapy Platform In New What This Means Segment CI
10-06 Ernexa Therapeutics Announces ERNA-101 Preclinical Data Selected For Flash Talk Presentation At Nature Conferences? Next-Generation Cancer Therapeutics Meeting Co-Hosted By MD Anderson Cancer Center CI
09-30 Ernexa Therapeutics Reports ERNA-101 Safety Results Across Three IND-Enabling Studies CI
09-17 Ernexa Therapeutics Announces Appointment of Robert J. Spiegel to Board of Directors CI
09-15 Ernexa Therapeutics Reports Positive Disease-Modifying Preclinical Data For ERNA-201 And Accelerates ERNA-101 Toward First-In-Human Dosing CI
08-10 Ernexa Therapeutics Announces Appointment of David Polinsky to Board of Directors CI
08-06 Tranche Update on Ernexa Therapeutics Inc.'s Equity Buyback Plan announced on November 25, 2024. CI
08-06 Ernexa Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
07-15 Ernexa Therapeutics Says Preclinical Data Shows Anti-Tumor Activity of ERNA-101 Combination MT
07-15 Ernexa Therapeutics Receives Independent Validation Of ERNA-101 With Complete Tumor Clearance And Durable Survival In Ovarian Cancer Models Ahead Of Planned Clinical Entry CI
06-26 Ernexa Therapeutics Inc. Announces Resignation of Sandra Gurrola from Senior Vice President of Finance, Effective July 3, 2026 CI
06-17 Ernexa Therapeutics Positioned to Become A Clinical-Stage Biotechnology Company as ERNA-101 on Track for Planned Third Quarter 2026 IND Submission and First-In-Human Study CI
06-17 Ernexa Therapeutics Says Investigational New Drug Submission for ERNA-101 on Track for Q3 MT
1 day-6.15%
1 week-2.12%
Current month-39.44%
1 month-43.74%
3 months-50.69%
6 months-59.56%
Current year-93.54%
1 week 1.92
Extreme 1.92
2.26
1 month 1.84
Extreme 1.8387
3.74
Current year 1.84
Extreme 1.8387
35
1 year 1.84
Extreme 1.8387
71.5
3 years 1.84
Extreme 1.8387
984.37
5 years 1.84
Extreme 1.8387
74,999.96
10 years 1.84
Extreme 1.8387
605,024.7
Manager TitleAgeSince
Chief Executive Officer 64 31/12/2023
Director of Finance/CFO 63 09/08/2026
Chief Tech/Sci/R&D Officer 61 -
Director TitleAgeSince
Director/Board Member 67 06/06/2022
Chairman 79 18/12/2023
Director/Board Member 64 31/12/2023
Date Insider Type Main position Quantity % Market Cap. Importance
31/08/26 Free

Director

5,944 0.3641%
31/08/26 Free

Director

5,943 0.3641%
31/08/26 Free

Director

5,083 0.3114%
Change 5-day change 1-year change 3-year change Capi.($)
-6.15%-2.12%-93.75%-99.65% 3.37M
+0.88%-0.34%+40.64%+73.05% 64.69B
-0.26%+6.91%+11.14%+77.36% 54.78B
+0.47%+3.52%+8.22%+100.95% 53.49B
-2.06%+2.90%+24.07%+48.36% 45.98B
-1.79%+0.19%+19.32%+123.62% 42.94B
-1.65%+0.96%+237.56%+823.66% 40.08B
-2.26%-4.14%+15.38%+45.53% 33.52B
-2.61%-10.65%+19.96%-6.35% 23.97B
+12.10%+16.60%+55.14%+46.15% 23.67B
Average -0.33%+1.02%+33.77%+123.27% 38.31B
Weighted average by Cap. -0.05%+1.62%+45.51%+149.75%

Financials

2026 *2027 *
Net sales - -
Net income -19.98M -17.86M -16.53M -14.96M -28M -1.9B -28.46M -199M -78.66M -994M -74.97M -73.37M -3.15B -21M -18.78M -17.37M -15.73M -29.44M -2B -29.92M -209M -82.69M -1.04B -78.81M -77.13M -3.31B
Net Debt - -
Projected Income Statement - Annual - Ernexa Therapeutics Inc.
Logo Ernexa Therapeutics Inc.
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Employees
6
Date Price Change Volume
26/10/26 US$1.938 -6.15% 11,179
23/10/26 US$2.065 -0.48% 5,931
22/10/26 US$2.075 -1.66% 16,467
21/10/26 US$2.110 -5.80% 9,569
20/10/26 US$2.240 +13.13% 48,186
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.938USD
Average target price
30.00USD
Spread / Average Target
+1,447.99%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Ernexa Therapeutics Inc.
  1. Stock Market
  2. Stocks
  3. ERNA Stock